Clairity, Myriad Genetics, and MagView Launch First Integrated AI-Genetic Risk Platform for Breast Cancer Screening
核心洞察
Clairity (搜索), Myriad Genetics (搜索), and MagView (搜索) have announced a joint collaboration to launch the first integrated AI and genetic risk platform for personalized breast health assessment.
The platform combines Clairity (搜索)'s FDA-authorized AI mammogram analysis with Myriad's MyRisk (搜索) hereditary cancer testing through MagView (搜索)'s Luminary Risk (搜索) software.
This integration aims to identify more women at high risk for breast cancer by providing clinicians with both genotype and phenotype data in a unified workflow.
Three leading companies in breast cancer care have announced a groundbreaking collaboration to launch the first integrated artificial intelligence and genetic risk assessment platform for personalized breast health. Clairity (搜索), Myriad Genetics (搜索), Inc. (NASDAQ: MYGN), and MagView (搜索) revealed their joint effort on November 25, 2025, aimed at identifying more women at high risk for breast cancer while addressing critical gaps in risk assessment without creating additional administrative burdens.
Revolutionary Integration of AI and Genetic Testing
The collaboration brings together three specialized leaders in breast cancer care. Clairity (搜索) has developed Clairity Breast (搜索), the first and only FDA-authorized offering to estimate a woman's five-year breast cancer risk directly from a routine mammogram. Myriad Genetics (搜索) offers the MyRisk (搜索)® Hereditary Cancer Test with RiskScore®, which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk. MagView (搜索) provides comprehensive software solutions for breast imaging centers through its Luminary Risk (搜索) platform.
For the first time, clinicians and patients will have access to an integrated view of both genotype (Myriad's MyRisk (搜索) with RiskScore test) and phenotype (Clairity Breast (搜索)) through MagView (搜索)'s Luminary Risk (搜索) platform, which supports breast cancer risk assessment programs across the United States.
Enhanced Clinical Decision-Making
"By integrating directly with MagView (搜索) alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone," said Jeff Luber, CEO of Clairity (搜索). "Using AI-powered risk assessment, Clairity Breast (搜索) identifies women at the highest risk from a routine mammogram."
The integration represents a significant advancement in personalized medicine for breast cancer screening. Sam Raha, President and CEO of Myriad Genetics (搜索), emphasized the clinical importance: "Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum. By pairing the MyRisk (搜索) Hereditary Cancer Test with Clairity (搜索)'s AI-powered risk assessment within MagView (搜索)'s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer."
Streamlined Workflow Implementation
The platform addresses workflow efficiency challenges that have historically hindered comprehensive risk assessment implementation. Bryan Chapin, President and CEO of MagView (搜索), explained: "Our platform streamlines how risk information is captured, interpreted, and acted on. Integrating Clairity (搜索) and MyRisk (搜索) into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency."
MagView (搜索)'s Luminary Risk (搜索) software embeds into electronic health records (EHRs) to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. The platform is currently utilized by more than 2,500 facilities across the United States, including many of the nation's top cancer centers.
Technology Components
Clairity Breast AI Platform
Clairity (搜索)'s flagship product transforms medical imaging into a predictive tool for early risk assessment. The FDA-authorized offering estimates a woman's five-year breast cancer risk directly from routine mammograms, shifting care from detection to prevention. The technology empowers health systems, radiologists, and women to act earlier, potentially saving lives and lowering the overall cost of cancer care.
MyRisk Hereditary Cancer Test
Myriad Genetics (搜索)' MyRisk (搜索) test with RiskScore combines multiple risk factors including genetics, clinical factors using the Tyrer-Cuzick model, and polygenic risk scores. This comprehensive approach provides molecular insights that can significantly improve patient care and lower healthcare costs across medical specialties.
MagView's Luminary Risk Platform
As a leader in breast imaging workflow solutions, MagView (搜索) provides comprehensive software for mammography reporting, tracking, workflow, compliance, and high-risk screening. The Luminary Risk (搜索) platform is designed to integrate seamlessly with existing healthcare infrastructure while maintaining focus on patient experience and operational efficiency.